Medical management of stable coronary artery disease

American Family Physician

Volumn 83, Issue 7, 2011, Pages 819-826

  Pflieger, Matthew ^a   Winslow, Bradford T ^b   Mills, Kyle ^c   Dauber, Ira M ^d  

^a Clinica Campesina Family Health Services   (United States)

^b Bend Memorial Clinic ^*

^c Bend Memorial Clinic   (United States)

^d South Denver Cardiology Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; ATENOLOL; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEZAFIBRATE; BISOPROLOL FUMARATE; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CARVEDILOL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EZETIMIBE; FENOFIBRATE; GEMFIBROZIL; LABETALOL; LOSARTAN POTASSIUM; METOPROLOL; NITRATE; PLACEBO; PRAVASTATIN; PROPRANOLOL; RAMIPRIL; SIMVASTATIN; TELMISARTAN; TIMOLOL; UNINDEXED DRUG;

ANGINA PECTORIS; ARTICLE; BLEEDING; BRONCHOSPASM; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; CREATINE KINASE BLOOD LEVEL; DOSE RESPONSE; DRUG APPROVAL; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG WITHDRAWAL; HEALTH CARE QUALITY; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; LIVER FUNCTION TEST; MYALGIA; PERIPHERAL OCCLUSIVE ARTERY DISEASE; RECOMMENDED DRUG DOSE; RHABDOMYOLYSIS; SECONDARY PREVENTION; SIDE EFFECT; STROKE;

EID: 79956368956     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee [published corrections appear in Circulation. 2009;119(3):e182, and Circulation. 2010;122(1):e11]. Circulation. 2009;119(3):e21-e181.
2. Third report of the National Cholesterol Education Program Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). NIH Publication No. 02-5215. September 2002.
3. Fraker TD, Fihn SD, Gibbons RJ, et al. 2007 chronic angina focused update of the ACC/AHA 2002 Guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 Guidelines for the management of patients with chronic stable angina [published correction appears in Circulation. 2007;116(23):e558]. Circulation. 2007;116(23):2762-2772.
4. Sacks FM, Moyé LA, Davis BR, et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation. 1998;97(15):1446-1452.
5. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7-22.
6. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339(19):1349-1357.
7. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383-1389.
8. Josan K, Majumdar SR, McAlister FA. The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials. CMAJ. 2008; 178(5):576-584.
9. Secondary prevention by raising HDL cholesterol and reducing triglycer-ides in patients with coronary artery disease: the Bezafbrate Infarction Prevention (BIP) study. Circulation. 2000;102(1):21-27.
10. Cannon CP, Braunwald E, McCabe CH, et al.; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes [published correction appears in N Engl J Med. 2006;354(7):778]. N Engl J Med. 2004;350(15):1495-1504.
11. LaRosa JC, Grundy SM, Waters DD, et al.; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425-1435.
12. Baigent C, Keech A, Kearney PM, et al.; Cholesterol Treatment Trialists' (CTT) Collaborators. Effcacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [published corrections appear in Lancet. 2005; 366(9494):1358, and Lancet. 2008;371(9630):2084]. Lancet. 2005;366 (9493):1267-1278.
13. ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus [published correction appears in N Engl J Med. 2010; 362(18):1748]. N Engl J Med. 2010;362(17):1563-1574.
14. Lexi-Comp (Lexi-Drugs) [computer program]. Hudson, Ohio: Lexi-Comp; 2009.
15. Rubins HB, Robins SJ, Collins D, et al.; Veterans Affairs High-Density Lipo-protein Cholesterol Intervention Trial Study Group. Gemfbrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 1999;341(6):410-418.
16. Kastelein JJ, Akdim F, Stroes ES, et al.; ENHANCE Investigators. Simvas-tatin with or without ezetimibe in familial hypercholesterolemia [published correction appears in N Engl J Med. 2008;358(18):1977]. N Engl J Med. 2008;358(14):1431-1443.
17. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. NIH Publication No. 04-5230. August 2004.
18. Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention [published correction appears in Circulation. 2007; 116(5):e121]. Circulation. 2007;115(21):2761-2788.
19. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies [published correction appears in Lancet. 2003; 361(9362):1060]. Lancet. 2002;360(9349):1903-1913.
20. Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2008;51(15):1512-1524.
21. Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis. Ann Intern Med. 2002;137(9):715-725.
22. Freemantle N, Cleland J, Young P, Mason J, Harrison J. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999;318(7200):1730-1737.
23. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomized trials in the context of expectations from prospective epide-miological studies. BMJ. 2009;338:b1665.
24. Heidenreich PA, McDonald KM, Hastie T, et al. Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina. JAMA. 1999;281(20):1927-1936.
25. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G; The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients [published corrections appear in N Engl J Med. 2000;342(10):748, and N Engl J Med. 2000;342(18):1376]. N Engl J Med. 2000;342(3):145-153.
26. Fox KM; EURopean trial on reduction of cardiac events with Per-indopril in stable coronary Artery disease Investigators. Effcacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003; 362(9386):782-788.
27. Rodrigues EJ, Eisenberg MJ, Pilote L. Effects of early and late administration of angiotensin-converting enzyme inhibitors on mortality after myocardial infarction. Am J Med. 2003;115(6):473-479.
28. Dickstein K, Kjekshus J; Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet. 2002; 360(9335):752-760.
29. Pfeffer MA, McMurray JJ, Velazquez EJ, et al.; Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both [published correction appears in N Engl J Med. 2004; 350(2):203]. N Engl J Med. 2003;349(20):1893-1906.
30. Yusuf S, Teo KK, Pogue J, et al.; ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547-1559.
31. Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation. 1995; 92(5):1326-1331.
32. Nissen SE, Tuzcu EM, Libby P, et al.; CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: The CAMELOT Study: a randomized controlled trial. JAMA. 2004;292(18):2217-2225.
33. Julius S, Kjeldsen SE, Weber M, et al.; VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363(9426):2022-2031.
34. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med. 1992;326(4):242-250.
35. Becker RC, Meade TW, Berger PB, et al.; American College of Chest Physicians. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 suppl):776S-814S.
36. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myo-cardial infarction, and stroke in high risk patients [published correction appears in BMJ. 2002;324(7330):141]. BMJ. 2002;324(7329):71-86.
37. Berger JS, Brown DL, Becker RC. Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis. Am J Med. 2008;121(1):43-49.
38. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348(9038):1329-1339.
39. Bhatt DL, Fox KA, Hacke W, et al.; CHARISMA Investigators. Clopido-grel and aspirin versus aspirin alone for the prevention of atherothrom-botic events. N Engl J Med. 2006;354(16):1706-1717.